GuruFocus.com

Tesaro Inc (TSRO) Files 10-K for the Fiscal Year Ended on December 31, 2017

GuruFocus.com

In This Article:

- By insider

Tesaro Inc (TSRO) files its latest 10-K with SEC for the fiscal year ended on December 31, 2017. Tesaro Inc is an oncology-focused biopharmaceutical company. It focuses on developing treatments for cancer. Tesaro Inc has a market cap of $3 billion; its shares were traded at around $55.23 with and P/S ratio of 17.93.


For the last quarter Tesaro Inc reported a revenue of $142.8 million, compared with the revenue of $16.99 million during the same period a year ago. For the latest fiscal year the company reported a revenue of $223.3 million, an increase of 398.2% from last year. For the last five years Tesaro Inc had an average revenue decline of 0% a year.

The reported loss per diluted share was $9.17 for the year, compared with the loss per share of $4.79 in the previous year. The Tesaro Inc had an operating margin of -214.72%, compared with the operating margin of -827.59% a year before. The 10-year historical median operating margin of Tesaro Inc is -37644.40%. The profitability rank of the company is 4 (out of 10).

At the end of the fiscal year, Tesaro Inc has the cash and cash equivalents of $643.1 million, compared with $785.9 million in the previous year. The long term debt was $437.1 million, compared with $131.8 million in the previous year. The interest coverage to the debt is at a comfortable level of 15.6. Tesaro Inc has a financial strength rank of 6 (out of 10).

At the current stock price of $55.23, Tesaro Inc is traded at 87.8% discount to its historical median P/S valuation band of $451.54. The P/S ratio of the stock is 17.93, while the historical median P/S ratio is 146.70. The stock lost 70.68% during the past 12 months.

For the complete 20-year historical financial data of TSRO, click here.

This article first appeared on GuruFocus.


and

Recommended Stories